Journal
JOURNAL OF CONTROLLED RELEASE
Volume 164, Issue 2, Pages 177-182Publisher
ELSEVIER
DOI: 10.1016/j.jconrel.2012.07.045
Keywords
Nanoparticles; Targeting; Barriers; Photothermal ablation therapy
Funding
- National Institutes of Health [RC2 GM092599]
- Center of Cancer Nanotechnology Excellence grant [U54 CA151668]
- John S. Dunn Foundation
Ask authors/readers for more resources
Advances in nanotechnology for oncology will arise from an increased understanding of the interaction between nanomaterials and biological systems; refinement of multifunctional nanocomposites for applications such as simultaneous imaging and therapy (theranostics); and harnessing of the unique physicochemical properties arising from nanoscale effects which distinguish them from small-molecular-weight molecules in the detection and destruction of cancer cells with high selectivity and efficiency. The major challenges in successful clinical translation of tumor specific nanoparticle delivery include overcoming various biological barriers and demonstrating enhanced therapeutic efficacy over the current standard of care in the clinic. For many nanoparticle mediated theranostic applications, image guidance can play a crucial role not only in exploiting the cancer specific imaging capabilities of these novel particles, but in planning, targeting, monitoring and verifying treatment delivery, thus enhancing the safety and efficacy of these emerging procedures. (C) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available